Wayne Holman, MD

Wayne Holman is the Founder Ridgeback Capital & Co-Founder Ridgeback Biotherapeutics

[Wayne Holman, MD @WayneRidgeback]

Ridgeback received FDA priority review for ansuvimab to treat Ebola and will donate free drug for those in need in Africa during this ongoing Ebola outbreak. https://t.co/dgjsEJ4LXn

[Wayne Holman, MD @WayneRidgeback]

Happy to join forces to vanquish SARS-CoV-2 with our great partner Merck $MRK

https://t.co/sTaW622dos

[Wayne Holman, MD @WayneRidgeback]

Thanks to the great team at Ridgeback Bio for getting this promising medicine to patients in record time. https://t.co/4M2KY6DrZl

[Wayne Holman, MD @WayneRidgeback]

MHRA clearance Thursday April 9. 80 people screened for Phase 1 on Good Friday. 1st person to receive EIDD-2801 this morning in the UK. Amazing teamwork. Fastest trial start ever. Go Ridgeback Go. #CureCovid19 #Covid19 #Ridgebackbio
https://t.co/i0FMOYwOyn

[Wayne Holman, MD @WayneRidgeback]

@llborio @EmoryMedicine Thanks Dr. Borio. Ridgeback Biotherapeutics is collaborating with George Painter and will be taking this into human studies in the next few days.

[Wayne Holman, MD @WayneRidgeback]

@WalkerStapleton Thanks Walker. FDA cleared EIDD-2801 to start human trials last Friday. Ridgeback Bio will start trials in a few days.

[Wayne Holman, MD @WayneRidgeback]

@ScottGottliebMD EIDD-2801 is oral, easy scalable CMC, can be used early in disease at home. Much less expensive manufacturing vs antibodies. Prevents severe disease in animal models of MERS and SARS.

[Wayne Holman, MD @WayneRidgeback]

@martinvars Hi Martin, Follow me @WayneRidgeback We have an oral drug for COVID19. FDA cleared us to go into human studies. It prevents severe disease in animals with MERS and SARS. We hope to show the same in humans with COVID19. Happy to see you are well.

[Wayne Holman, MD @WayneRidgeback]

Thanks to Tim Sheahan, Mark Denison, Ralph Baric, George Painter, Wendy Painter for all the great research on EIDD-2801. Human trials to start in days. #COVID19 #CURECOVID

[Timothy Sheahan @timothysheahan]

Here is our new paper on an oral #antiviral drug that works against #SARSCoV2 #COVID19. A herculean effort w/ Amy Sims @Ardinajp @mariagoneviral @DenisonLab @KDinnon @aschaefe29 @SarahRLeist @Baric_Lab @DenisonLab @knowerofrandom https://t.co/4u38OKvpd8

[Wayne Holman, MD @WayneRidgeback]

Ridgeback to start human testing on EIDD-2801 within days. Oral investigational drug. Animal data in MERS and SARS shows early treatment prevents severe illness. We hope to prove the same in people with COVID-19. #COVID19 #CURECOVID19

[Wayne Holman, MD @WayneRidgeback]

Ridgeback announced today FDA cleared EIDD-2801 IND last Friday. Thank you FDA Comm. Hahn and Anti-Viral Division. So fast. So helpful. #COVID19 #FDA #EIDD2801 #RidgebackBiotherapeutics

[Wayne Holman, MD @WayneRidgeback]

Questions
1)Is there a relationship between severity of COVID-19 in 30-50 year olds and the exposure to RCCVs from kids through household (parents) and professional (MDs and teachers) contact?
2)Would greater prior exposure the RCCVs result in a milder COVID-19 disease course?

[Wayne Holman, MD @WayneRidgeback]

8)Prevalence of anti-RCCV antibodies declines with age in older adults
9)Antibodies to the RCCVs, SARS-COV-1 and MERS isolated from human samples can have some cross reactivity to each other

[Wayne Holman, MD @WayneRidgeback]

6)Adults with children are more frequently infected with the 4 RCCVs relative to adults without children
7)Teachers and pediatricians are more likely to be infected with the 4 RCCVs

[Wayne Holman, MD @WayneRidgeback]

3)Children are less likely to have severe disease with SARS-COV2
4)Younger kids will have had less exposure to RCCVs vs older kids
5)Within childhood age groups the youngest are more likely to have severe disease

[Wayne Holman, MD @WayneRidgeback]

Data reported in the medical literature:
1)There are 4 routinely circulating coronaviruses (RCCVs) that cause mild disease
2)Children are more routinely infected vs adults with the 4 RCCVs in published studies of subjects in NYC and China

[Wayne Holman, MD @WayneRidgeback]

Flattening the Curve: The South Korean Approach to COVID-19 https://t.co/p1vRAsFV9M

[Wayne Holman, MD @WayneRidgeback]

@AndyBiotech Flatten the curve. Give science time to bring effective drugs forward. Thx Andy for all the great info. https://t.co/L12Lpa4dCx

[Wayne Holman, MD @WayneRidgeback]

@DrMattMcCarthy @WEFBookClub Take a look at the data for EIDD-2801. IND filing next week. https://t.co/L12Lpa4dCx #CLEARTHEPATH #Coronavirus #COVID

[Wayne Holman, MD @WayneRidgeback]

https://t.co/L12Lpa4dCx